To evaluate DYRK1A as a potential target for the treatment of ALL, we first tested the extent to which in vitro pharmacologic inhibition of DYRK1A could induce apoptosis or cell cycle arrest in KMT2A-R ALL cells. The gene discussed is DYRK1A; the disease is acute lymphoblastic leukemia.